Chordia Therapeutics, Inc.
Privately held: no public share price
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | CLK (CDC-like kinase family)Small molecule | Acute Myeloid Leukemia |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (2)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $5.3M | $16M | — | report ↗ |
View 1 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | — | $5.3M | $22M | — | report ↗ |
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $9.6M | $17M | — | report ↗ |
Chordia Therapeutics, Inc. reported R&D spend of $9.56M, down 3.8% YoY, cash and equivalents of $17.34M, and a net loss of $11.97M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $9.9M | $30M | — | report ↗ |